Plasticity and immune marker profiling of tumour- and ascites-derived microtumours in serous ovarian cancer: relevance for short-term culture models
- 1Department of Gynecology, University Medical Center Hamburg-Eppendorf
- 22cureX
- 3Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf
Abstract
Introduction: Serous ovarian cancer (SOC) is characterized by tumour heterogeneity, cellular plasticity, and immune suppression, contributing to limited therapeutic responses. Understanding tumour -immune dynamics at the cellular level is essential for developing personalized treatment strategies.
Methods: We established a patient-derived microtumour (MT) platform from solid tumour tissue and malignant ascites of 18 treatment-naïve SOC patients. Using multiparametric flow cytometry, we analysed plasticity-associated markers (CD10, CD24, CD44, CD90, CD133), immunoregulatory molecules (PD-L1, PVR, PVRL2, CD47, Calreticulin, CD39, CD73), and antigen presentation molecules (HLA-A/B/C, HLA-DR/DP/DQ) during short-term culture.
Results: Plasticity-associated marker expression was largely conserved across compartments, with substantial interpatient heterogeneity and only modest differences in an exploratory composite plasticity score. Compared with tumour-derived MTs, ascites-derived MTs exhibited significantly higher calreticulin expression and lower expression of the ectonucleotidase CD39. Short-term culture induced CD44 upregulation and CD90 downregulation as well as dynamic modulation of immune markers, such as increased PVR and PVRL2 expression. HLA expression showed substantial interindividual heterogeneity rather than clear compartment-specific differences. Co-expression analyses revealed associations between plasticity-associated and immunoregulatory features, such as CD10/CD24 with PD-L1 and CD47. Finally, exploratory autologous co-cultures demonstrated the feasibility of combining patient-derived MTs with matched immune cells. Two of five samples showed moderate responses to anti-PD-L1 and anti-TIGIT, reflected by increased granzyme B expression and accompanied by compensatory changes in TIGIT and PD-L1 expression.
Discussion: Taken together, these findings indicate an association between tumour cell plasticity and an immune-evasive phenotype in ovarian cancer and support patient-derived MTs as an exploratory short-term platform for capturing patient-specific tumour -immune interactions, while highlighting dynamic immune checkpoint molecule expression during cultivation.
Related
- Extracellular flux analysis and proteomic profiling indicate ibogaine promotes synaptic plasticity and neural repair by a metabolic preconditioning mechanism
- Profiling perceived knowledge, relevance and interest across geriatric topics of health and social care professionals: multinational electronic cross-sectional survey.
- The Molecular Landscape of the Senescence-EMT Interplay: Deciphering Tumour Plasticity Through Molecular Signatures and Multi-Omic Profiling.
- Multiomics comparison between prostate cell lines and patient-derived tissue to evaluate cell line clinical relevance
- Plant-Derived Bioactive Compounds, Cancer Stemness and Cellular Senescence: A Narrative Review of Preclinical Evidence and Translational Relevance to Cancer Recurrence and Drug Resistance
BibTeX
@article{hell2026plasticity,
title = {{Plasticity and immune marker profiling of tumour- and ascites-derived microtumours in serous ovarian cancer: relevance for short-term culture models}},
author = {Louisa Hell and Yi Ding and Clara Pellens and Kathrin Eylmann and Maila Rossberg and Carsten Bokemeyer and Jürgen Kupper and Barbara Schmalfeldt and Franziska Brauneck and Jasmin Wellbrock and Tabea Sturmheit and Leticia Oliveira-Ferrer},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1901291},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1901291/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Plasticity and immune marker profiling of tumour- and ascites-derived microtumours in serous ovarian cancer: relevance for short-term culture models
AU - Louisa Hell
AU - Yi Ding
AU - Clara Pellens
AU - Kathrin Eylmann
AU - Maila Rossberg
AU - Carsten Bokemeyer
AU - Jürgen Kupper
AU - Barbara Schmalfeldt
AU - Franziska Brauneck
AU - Jasmin Wellbrock
AU - Tabea Sturmheit
AU - Leticia Oliveira-Ferrer
PY - 2026
DA - 2026/10/07
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1901291
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1901291/full
AB - Introduction: Serous ovarian cancer (SOC) is characterized by tumour heterogeneity, cellular plasticity, and immune suppression, contributing to limited therapeutic responses. Understanding tumour -immune dynamics at the cellular level is essential for developing personalized treatment strategies. Methods: We established a patient-derived microtumour (MT) platform from solid tumour tissue and malignant ascites of 18 treatment-naïve SOC patients. Using multiparametric flow cytometry, we analysed plasticity-associated markers (CD10, CD24, CD44, CD90, CD133), immunoregulatory molecules (PD-L1, PVR, PVRL2, CD47, Calreticulin, CD39, CD73), and antigen presentation molecules (HLA-A/B/C, HLA-DR/DP/DQ) during short-term culture. Results: Plasticity-associated marker expression was largely conserved across compartments, with substantial interpatient heterogeneity and only modest differences in an exploratory composite plasticity score. Compared with tumour-derived MTs, ascites-derived MTs exhibited significantly higher calreticulin expression and lower expression of the ectonucleotidase CD39. Short-term culture induced CD44 upregulation and CD90 downregulation as well as dynamic modulation of immune markers, such as increased PVR and PVRL2 expression. HLA expression showed substantial interindividual heterogeneity rather than clear compartment-specific differences. Co-expression analyses revealed associations between plasticity-associated and immunoregulatory features, such as CD10/CD24 with PD-L1 and CD47. Finally, exploratory autologous co-cultures demonstrated the feasibility of combining patient-derived MTs with matched immune cells. Two of five samples showed moderate responses to anti-PD-L1 and anti-TIGIT, reflected by increased granzyme B expression and accompanied by compensatory changes in TIGIT and PD-L1 expression. Discussion: Taken together, these findings indicate an association between tumour cell plasticity and an immune-evasive phenotype in ovarian cancer and support patient-derived MTs as an exploratory short-term platform for capturing patient-specific tumour -immune interactions, while highlighting dynamic immune checkpoint molecule expression during cultivation.
SN - 1664-3224
ER -